The objective of this retrospective study is to evaluate the impact of plerixafor administration compared to the use of G-CSF alone on the basis of the apheresis protocol collection efficacy, the targeted cell yield and harvest quality, as well as the engraftment kinetics in patients with PCN and lymphomas. The gene discussed is CSF3; the disease is lymphoma.